Šalis: Didžioji Britanija
kalba: anglų
Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)
Tolbutamide
Kent Pharma (UK) Ltd
A10BB03
Tolbutamide
500mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06010201; GTIN: 5015201006480
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TOLBUTAMIDE 500MG TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. • IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE ASK YOUR DOCTOR OR YOUR PHARMACIST. • THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU ONLY. DO NOT PASS IT ON TO OTHERS. IT MAY HARM THEM, EVEN IF THEIR SIGNS OF ILLNESS ARE THE SAME AS YOURS. • IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR OR PHARMACIST. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. SEE SECTION 4. WHAT IS IN THIS LEAFLET 1. What your medicine is and what it is used for 2. What you need to know before you take your medicine 3. How to take your medicine 4. Possible side effects 5. How to store your medicine 6. Contents of the pack and other information The dose is fixed by the doctor, depending on your blood and urine sugar levels. Changes in external factors (e.g. weight reduction, change in life style, stress) or improvements in the disease may require changed tolbutamide doses. The recommended doses are given below. • UNTREATED DIABETES - Initially two tablets daily. The maintenance dose will depend upon your response to treatment. The usual daily dose is 1-3 tablets daily. • CHANGE FROM OTHER TABLETS - You can usually change between different diabetes tablets without a break in treatment. Initially two tablets daily. The maintenance dose will depend upon your response to treatment. • CHANGE FROM INSULIN - Low insulin doses (less than 20 units) can be replaced immediately. With high insulin doses a gradual change is required. Insulin and tolbutamide will be given together and the insulin dose will be gradually reduced. If you do not achieve adequate control of your diabetes through diet and 4 tablets of Tolbutamide daily then your doctor may also give you another drug, such as metformin, to help you control your blood sugar levels. If you are run down or elderly or suffer from Perskaitykite visą dokumentą
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tolbutamide 500mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Tolbutamide 500mg 3. PHARMACEUTICAL FORM Tablet. White biconvex tablets, 13mm in diameter with a breakline; “T” above breakline and “500 below. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tolbutamide is indicated for the oral treatment of patients with non-insulin dependent diabetes (maturity-onset or type II diabetes) who respond inadequately to dietary treatment alone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The tablets may be taken as a single dose with, or immediately after, the first main meal of the day, or as a divided dose for optimum control of blood sugar. 1. Treatment of previously untreated diabetes. Stabilisation can be achieved by commencing with 2 tablets daily, and adjusting in the light of the patient’s individual response. The average daily dose is 1-3 tablets as a single or divided dose. In general, patients who do not respond to 4 tablets daily do not respond to higher doses. 2. Change over from other oral antidiabetics can usually be carried out without a break in therapy, starting with 2 tablets daily, followed by a maintenance dose depending on response 3. Combination with biguanides: If adequate control is not achieved with diet and 4 tolbutamide 500mg tablets daily, it can often be achieved by combined administration with biguanides. 4. Change-over from insulin: Some cases of non-insulin dependent diabetes previously treated with insulin can be changed to tolbutamide. Low insulin doses (less than 20 units) can be replaced immediately. With higher doses a gradual change is advisable. Children: Not recommended Elderly: treatment at a lower dose. Method of administration For oral use 4.3 Contraindications Hypersensitivity to the active ingredient or any of the excipients Should not be used in patients who have or have ever had diabetic ketoacidosis, who have insulin-dependent diabetes, serious impairment of ren Perskaitykite visą dokumentą